| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.26 | 9e-07 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.14 | 2e-05 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.2 | 3e-05 |
| mRNA | 16-beta-bromoandrosterone | CTRPv2 | pan-cancer | AAC | 0.15 | 5e-05 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | -0.19 | 7e-05 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.2 | 0.0003 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0007 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.35 | 0.0008 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.001 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |